Brief Summary: 322 HIV-positive inpatients with tuberculosis were characterised. 2-month mortality was 31%, and dissemination was common. Older age, being male, taking antiretroviral therapy at admission, poor nutritional status and positive urine-diagnostics were associated with mortality. Interventions to reduce mortality are needed.
Introduction
HIV-associated tuberculosis disease (HIV/TB) is a leading cause of mortality, accounting for 370,000 deaths globally in 2016 [1] . Much of this burden resides in patients admitted to hospitals in high HIVprevalence settings in Africa [2] . A meta-analysis estimated that TB caused 24% of admissions and 27% of deaths amongst HIV-positive inpatients, with 30% case fatality [3] . Post-mortem data suggest an even greater burden, as almost half of fatal TB remains undiagnosed [4] . However, these data predate widespread access to antiretroviral therapy (ART) and improved diagnostics such as the Xpert MTB/RIF assay.
There remains a scarcity of data on factors associated with mortality in HIV/TB. Post-mortems suggest TB as the predominant cause of death [4] , but substantial co-morbidity from other opportunistic infections and non-infectious conditions means that death with confirmed TB does not necessarily imply death from TB. Observational cohorts report low CD4 cell count and older age as associated with mortality, but these data mainly relate to ART naïve individuals, and include patients without bacteriologically-confirmed TB disease [5] [6] [7] . Disseminated HIV/TB, as indicated by MTB detection in blood or urine, is also common and is an independent predictor of mortality [8] [9] [10] .
Understanding factors associated with mortality in hospitalised patients with HIV/TB in the context of high ART coverage, rapid TB diagnostics with better yield, and prompt TB treatment could help inform strategies to identify high-risk patients, and interventions to reduce mortality. Here we describe characteristics of patients diagnosed with TB from the STAMP (Screening for TB to reduce AIDS related Mortality in hospitalised Patients) randomised controlled trial of urine-based TB screening in HIV-positive inpatients in Malawi and South Africa. [11] Our specific aims were to describe the clinical phenotypes, mortality and risk factors for mortality in hospitalised HIV/TB patients; the prevalence and mortality of disseminated TB; and the impact of ART and study site on mortality. 
Methods
This prospective cohort study was nested within the STAMP trial [11, 12] , which recruited adult HIVpositive patients, irrespective of clinical presentation, at admission to medical wards in two hospitals in Malawi and South Africa. Upon enrolment, patients were randomised to TB screening using sputum testing alone (standard of care, SOC), or sputum and urine testing (intervention). Primary outcome was all-cause mortality at 2-months, and secondary outcomes included TB diagnosis and treatment. Patients were excluded if they had TB treatment within 12 months, isoniazid preventative therapy (IPT) within 6 months, unable to provide informed consent, or been admitted for >48 hours at the time of screening.
Trial procedures are outlined in the Supplementary Methods [11, 12] . After enrolment, urine and spontaneously expectorated sputum samples were obtained and tested for TB according to trial arm. Patients allocated to the intervention arm underwent sputum testing (if produced) with Xpert MTB/RIF assay (Xpert), unconcentrated urine was tested with Determine TB-LAM Ag assay (TB-LAM), and concentrated urine was tested with Xpert [13] . Patients allocated to the SOC arm had sputum Xpert testing only: with urine immediately frozen. Clinical events during admission were recorded, and patients followed-up once at 2-months by interview. Patients not attending follow-up were contacted by telephone and/or home visit, with interview of next-of-kin to establish vital status if necessary.
Patients diagnosed with TB in the SOC trial arm (i.e. no real-time urine TB testing) had TB-LAM and Xpert testing performed on stored urine (Supplementary Methods). Patients were enrolled in this sub-study if they were diagnosed with TB and had positive laboratory tests (≥1 positive specimen on microscopy for AFB, Xpert, culture or TB-LAM) on any sample. Patients diagnosed or treated for TB without positive tests were excluded. The study was approved by the research ethics committee of the London School of Hygiene & Tropical Medicine, and local research ethics committees in Malawi and South Africa.
Definitions
Patients were defined as 'clinically suspected TB' if TB was recorded in the admitting differential diagnosis. Disseminated urinary TB was defined by any positive urine TB assay (TB-LAM or Xpert), and non-disseminated TB was a positive sputum TB assay with negative urine TB assays.
A urine 'TB score' was calculated based on the number of positive urine TB tests (TB-LAM or Xpert, possible values 0-2) [14] . The Supplementary Methods outlines other definitions. Mortality risk was calculated 56-days from admission. All baseline demographics, clinical variables, laboratory results and physiological measurements were considered for association with mortality using Cox proportional hazards models. An explanatory model was built excluding the most proximal factors on the causal pathway to mortality (notably, functional impairment). Separate models were built to assess associations of recruitment site with mortality. Models used step-wise backward elimination (variables with p>0.1 were excluded) and were restricted to complete cases. Nonlinearity of continuous variables was assessed using fractional polynomials.
Statistical analysis
Clinical phenotypes of HIV/TB patients were identified using unsupervised (i.e. without mortality outcome) hierarchical cluster analysis, with the number of clusters determined by stopping rules. 
Results

Patient characteristics
Between October 2015 and September 2017, 506 HIV-positive patients were diagnosed with TB, of whom 322 were laboratory-confirmed and included in this analysis. Similar numbers were from Malawi (155, 48.1%) and South Africa (167, 51.9%), with two-thirds (63.7%) clinically suspected to have TB (Table 1) Patients with disseminated TB were less likely to report a cough or to be clinically suspected of having TB. They were predominantly male and had more functional impairment (bedbound, unable to perform usual activities, and lower Karnofsky score); worse nutritional status (lower BMI and MUAC); were more likely to have WHO danger signs, sepsis and severe anaemia at presentation; and had lower CD4 cell counts (Table 1) . Eleven patients died before TB treatment initiation, while for those treated, median time from admission to treatment was 2 days (IQR 1 day). Four (1%) patients stopped TB treatment during hospitalisation due to treatment side-effects. Eleven patients were diagnosed with rifampicinresistant TB: six from sputum Xpert only, four from urine Xpert only, and one on both urine and sputum Xpert.
Mortality
Overall, 99 (30.7%) patients died by 56-days. Six patients were lost to follow-up after discharge.
Mortality in HIV/TB patients did not differ by STAMP trial arm (p=0.30), consistent with mortality benefit in the trial being restricted to patients with missed TB diagnoses (and therefore not included in this analysis) [11] . Median time to death was 12 days (IQR 5-27), and 71.7% (71/99) occurred during admission, with 9 (9.1%) within 48 hours and 32 (32.3%) within 7 days of admission ( Supplementary Figure 1 ).
Mortality was lowest in patients with negative urine TB tests (19.7% by 56-day), compared to disseminated urinary TB with one (30.5%) or two (40.7%) positive urine tests (p=0.018). Reduced functional ability (lower Karnofsky score, self-reported reductions in mobility, self-care and usual activities) and poor nutritional status (MUAC and BMI) were strongly associated with mortality (Table 3 ). Mortality was also associated with lower CD4, haemoglobin and renal impairment, although not with WHO danger signs.
In the multivariable model (n=320 , Table 3 ), mortality was independently associated with advancing age, male gender, lower MUAC, lower haemoglobin and higher urine TB score. CD4 cell count was not independently associated with mortality.
Not taking ART at admission was associated with a lower mortality than taking ART at admission in an unadjusted model (HR 0.6, p=0.035, Supplementary Figure 2 
Clinical Phenotype
Cluster analysis identified four distinct groups of patients based on correlation of clinical features at admission. Although not informed by outcome data, mortality differed substantially between these groups (Figure 1 , HR 2.4 for group 2, 4.5 for group 3 and 6.7 for group 4 compared to group 1, p<0.001). Group 1 (lowest mortality risk, 9.8% [5/51]) were more likely to be ART naïve, have better reported problems with usual activities, most had WHO danger signs and severe anaemia, and men predominated. Median CD4 counts were 78 and 38 cells/µl respectively. Clinical phenotype was also strongly associated with disseminated TB: groups 3 and 4 had the highest proportion of urinepositive patients (83% and 86% respectively compared to 55% in group 1, p<0.001).
Non-TB management
Broad-spectrum antibiotics (ceftriaxone, amoxicillin-clavulanic acid or co-trimoxazole) were given to 86.0% (277/322) of patients, with median duration 6 days (IQR 4-7 days). 45.1% (125/277) received two or more different antibiotics. 10.6% (10/94) of patients tested were cryptococcal antigen positive. Median duration of hospital stay was 10 days (IQR 5-15 days). Of the ART naïve patients surviving to discharge, 65.3% (49/75) commenced ART during the study, with median time to starting ART being 19 days (IQR 9-29). ART was started in 66.7% (14/21) of those who had discontinued ART, and 8.3% (1/12) ART naïve patients who died during admission.
14.8% (37/250) of patients discharged were readmitted to hospital during the 56-day follow-up, with readmission associated with higher mortality (24% vs 9%, p=0.006). Outpatient attendance was also common, with patients discharged having a median of 2 (IQR 1-4) clinic attendances by 56 days.
Patients dying after discharge were less likely to attend outpatient clinics (median 0 attendances [IQR 0-1] compared to 3 [IQR 1-4] for survivors, p<0.001). 
Discussion
The main findings were that two-month mortality in patients with HIV-associated TB was substantial (31%) despite good ART coverage, TB screening and prompt TB treatment. Urine diagnostic tests (likely defining disseminated TB) were positive in 78.0% of TB patients, and were associated with higher mortality. Despite most patients being established on ART, advanced immunosuppression and poor virologic control were common, and we report higher mortality in patients taking ART at TB diagnosis. Hierarchical cluster analysis defined four distinct clinical phenotypes with highly variable mortality (9.8% to 52.5%), suggesting that baseline risk-profiles could be used to prioritise patients for intensified care.
Our observed early mortality is close to that estimated for HIV-associated TB from other studies [3, 15] , and was high in both South Africa (25.5%) and Malawi (34.8%). This 9.3% unadjusted risk difference indicates the magnitude of effect that could be attributed to the better resources in South Africa (upper middle income) compared to Malawi (low income). Irrespective of cause of admission, HIV-positive inpatients do badly, with early mortality risks of 20-30% reported consistently for sub-Saharan Africa [16] . However, patients with disseminated TB do consistently worse than others. In the STAMP trial, for instance, HIV-positive inpatients without confirmed TB had 2-month mortality of 16.5%, below that of urine-positive TB, although similar to TB diagnosed only through sputum [11] .
In this context, TB-LAM or urine Xpert positivity was associated with a severely ill clinical phenotype.
This was also observed in a South African cohort, where markers of TB dissemination were associated with increased immune activation, which may contribute to mortality through tissue damage and organ dysfunction [15] . If we assume that positive urine results provide more rapid, less costly, and more sensitive equivalent of mycobacteraemia [15, 17, 18] , then these simple prognostic markers could be used to target additional interventions to reduce mortality, as well as being used for TB diagnosis.
TB patients taking ART ≥6 months had median CD4 count of only 96 cells/µL, with half having high viral loads (median 557,000 copies/mL). This strong relationship between disseminated TB and immunosuppression in patients taking ART prior to admission suggests that urine-positive TB could be an indicator of ART treatment failure. With successful scale-up of HIV-diagnosis and ART, the case-mix of inpatients has changed from predominantly ART-naïve [19] to that reported here: 80% with a known HIV-diagnosis taking ART. Interesting, this corresponds with a reversal in the prognostic value of ART prior to TB diagnosis, from beneficial [20, 21] to a risk-factor for mortality [22] . Therefore, patients with TB should be immediately evaluated and managed for virological failure. However, facilities for rapid viral load testing are not universally available in inpatient A c c e p t e d M a n u s c r i p t 10 settings [23] . Also, the impending roll-out of Dolutegravir in the region may impact the degree of ART failure seen amongst inpatients [24] .
Using both regression and cluster analysis, we found more severe functional impairment, worse nutritional status and severe anaemia being associated with both higher mortality and disseminated HIV/TB. Our findings support those reported in seriously ill HIV-positive inpatients with cough, where functional impairment (but not all WHO danger signs) were associated with poor outcomes [22] . The remarkably high mortality (50%) in those reporting severe functional impairment highlights the importance of upstream interventions to prevent TB, support early diagnosis, and improve recognition of critically-ill patients in community settings. Most patients reached their critically-ill state despite attending HIV-care services: empowering patients to promptly seek care could contribute to better outcomes.
Intervening to avert mortality in HIV/TB patients after admission maybe challenging (table 4) .
However, only one-third of deaths occurred within 1 week, suggesting a potential window of opportunity. The best strategy for supportive care in African hospitals with high HIV and TBprevalence remains unclear, with early fluid resuscitation leading to increased mortality in patients with sepsis [25] . Although provision of broad-spectrum antibiotics in our cohort was almost universal, resistance to first-line antibiotics in study hospitals is now commonplace, especially in Enterobacteriaceae through extended spectrum β-lactamases [26] . Although Schutz et al [15] found TB, rather than bacterial coinfection, as the major cause of mortality in HIV-positive inpatients, empirical antimicrobial agents have been associated with lower mortality in advanced HIV [27] .
Future strategies should account for antimicrobial resistance, and also target TB related mortality, for instance trialling high-dose rifampicin and/or host-directed therapies [28, 29] .
Cryptococcal meningitis is also a common cause of death in advanced HIV, and may be associated with HIV/TB [30, 31] . Despite exclusion of patients with altered conscious level, CrAg positivity was over 10%, supporting screening and treatment of cryptococcal infection in this population. Anaemia has previously been associated with poor outcomes in HIV/TB [32] , and this was also shown in this study. There are currently no normative guidelines on managing anaemia or blood transfusion in HIV/TB, and further research is needed before recommendations can be made [33] .
Almost one-third of deaths occurred after discharge, and those who died were less likely to attend outpatient clinics for follow-up. One-third of ART-naïve patients discharged alive had not commenced ART by 2-months, despite guidelines advocating early ART. This supports more intensive follow-up and support at discharge as a possible intervention to reduce mortality. Weekly follow-up was part of an intervention which reduced mortality in patients with low CD4 counts starting ART, and warrants evaluation in HIV/TB [34] .
The strengths of this study include its being nested within a TB screening trial, that management was undertaken by routine health services, and that these data reflect the high ART coverage for the Southern Africa region. Limitations include suboptimal sensitivity of the TB screening algorithms, notably for the sputum-only arm of the parent trial. Our definition of confirmed TB included some patients who were only TB-LAM positive, and we cannot exclude a small number of false positives [35, 36] . Sputum induction, which has been shown to increase the yield of sputum Xpert, was not available in this study [37] . Finally, we do not have post-mortem data.
In summary, we have shown high mortality in hospitalised patients with HIV-associated TB despite Continuous variables were all modelled as linear after checking for departures from linearity. For continuous variables, HR is for every unit increase in the variable, except for CD4 count where HR is for every 50 cells/µL increase. Urine TB score was modelled as a continuous linear variable. All p-values calculated using likelihood ratio testing. $ Missing data: 1 missing haemoglobin, 93 missing C-reactive protein, 225 missing eGFR. # Variable excluded from multivariable model as distal on causal pathway to death. CRP and eGFR were excluded from the multivariable model due to >25% missing data. The following variables were excluded due to collinearity: BMI was colinear with weight; WHO stage was colinear with CD4 count; TB-LAM and urine Xpert were colinear with urine TB score. All other variables with p>0.1 in univariable analysis were entered into the multivariable model using backwards stepwise elimination (variables exited the model if P>0.1), n=321. *Variables eliminated from the multivariable model. ART is antiretroviral therapy, BMI Body Mass Index, CI confidence interval, eGFR estimated glomerular filtration rate, EQ5D EurQol 5 Dimension, HR Hazard Ratio, MUAC mid-upper arm circumference, WHO World Health Organization. M a n u s c r i p t 23 A is a heat map comparing characteristics of clinical phenotype groups (from cluster analysis) to the overall population. Overall n=317, group 1 n=51, group 2 n=102, group 3 n=105, group 4 n=59. For continuous variables (marked with *), colours represent a ratio of mean or median values for the group compared to the overall mean or median. For categorical variables, the ratio is the group proportion compared to the overall proportion. Dark purple ( ) represents a ratio >1.6, and white ( ) represents a ratio <0.4. Missing data: 1 missing haemoglobin, 2 missing second-line ART regimen, 93 missing C-reactive protein, 222 missing HIV viral load. EQ5D variables are the proportion reporting 'no problem'. Time on ART and second-line ART are restricted to patients reporting current ART use.
Figure Legends
B Kaplan-Meier plot of time to death by clinical phenotype group. Grey dashed vertical line represents median length of hospital stay (10 days). Hazard ratio (HR) compared to group 1 is 2.4 (95%CI 0.9-6.3) for group 2, 4.5 (95%CI 1.8-11.4) for group 3 and 6.7 (95%CI 2.6-17.3) for groups, p<0.001.
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